U.S. Stock News

Radian Group (NYSE:RDN) has agreed to acquire specialty insurer and reinsurer Inigo, expanding beyond its core mortgage insurance business. The deal adds specialty P&C and reinsurance exposure to Radian's portfolio, reshaping the company's overall business mix. This transaction marks a meaningful shift in Radian's long term risk profile and revenue sources away from exclusive reliance on the US housing market. For investors watching Radian Group at a share price of $33.97, this move arrives...

A leading hedge fund manager has highlighted MercadoLibre (NasdaqGS:MELI) as a top long term growth idea. The manager pointed to MercadoLibre's e-commerce and fintech ecosystem in Latin America as a key reason for conviction. The endorsement referenced potential for substantial business growth by 2030, supported by market share gains and logistics scale. For investors tracking MercadoLibre at a current share price of $1,710.37, this call comes after a mixed return profile. The stock is up...

PVH Corp. recently reported its fourth-quarter and full-year 2025 results, with quarterly sales rising to US$2,505.1 million but swinging from net income of US$157.2 million to a net loss of US$158.3 million, while full-year net income fell sharply despite higher annual sales of US$8,950.2 million versus US$8,652.9 million previously. Behind the headline loss, PVH delivered adjusted earnings per share well above expectations, driven by Calvin Klein and Tommy Hilfiger, and outlined plans to...

Event context and recent price performance Vistance Networks (VISN) has drawn fresh attention after its recent rebranding from CommScope Holding Company, with shares last closing at $18.75 and showing positive moves over the past week and month. See our latest analysis for Vistance Networks. The recent rebrand comes alongside strong momentum, with an 8.95% 1 month share price return and a very large 1 year total shareholder return of 415.11%, which contrasts with more modest gains over...

Regeneron Pharmaceuticals (REGN) is back in focus after the US FDA approved extended dosing intervals for EYLEA HD in wet age related macular degeneration and diabetic macular edema, easing treatment schedules for eligible patients. See our latest analysis for Regeneron Pharmaceuticals. At a share price of $763.04, Regeneron has a 1 year total shareholder return of 33.94%, while its year to date share price return is slightly negative. This suggests that longer term momentum has been strong...

In early April 2026, iQIYI Inc. launched Nadou Pro, described as China’s first AI agent tailored for professional film and TV production, integrating its QiZhi multimodal models with third‑party tools to support end‑to‑end workflows from scriptwriting to final output. This move foregrounds iQIYI’s push to embed AI directly into premium content creation, potentially reshaping how it develops long‑form narratives across film, drama, and animation. We’ll now explore how Nadou Pro’s integrated...

If you are wondering whether Newmont at around US$112.83 is still attractively priced after a strong run, the key is to look closely at what the current share price implies about future value. The stock has delivered a 9.4% return over the last 7 days, is up 11.5% year to date and 154.8% over the past year, while the 30 day return of 3.0% suggests some recent pullback along the way. Recent headlines around Newmont have focused on the company within the broader materials sector and how...

In March 2026, Fox subsidiary Tubi announced a broad slate of new ad technology, Gen Z– and sports-focused original programming, and high-profile partnerships, including exclusive free F1 altcasts with Apple TV in the U.S., at the IAB NewFronts in New York. By tying advanced pause ads, contextual Scene Sense targeting, CTV-to-mobile Connected Conversions, and box office attribution with Fandango together, Tubi is positioning its free streaming platform as a data-rich, performance-focused...

Event context and recent performance snapshot Packaging Corporation of America (PKG) is drawing investor attention after recent share price moves, with the stock up about 0.5% over the past day but showing declines over the week, month, and past 3 months. See our latest analysis for Packaging Corporation of America. That 0.5% 1 day share price return sits against a weaker recent pattern, with the 30 day share price return of 7.7% and year to date share price return of 2.7% both in decline. At...

Earnings, guidance and new financing reshape the Sigma Lithium story Sigma Lithium (SGML) has just paired a US$100 million bank guarantee for its second Greentech plant with full year 2025 earnings and multi year production guidance, giving investors fresh data on growth plans and current financial performance. See our latest analysis for Sigma Lithium. At a share price of US$14.51, Sigma Lithium has seen a 21.7% 7 day share price return and 17.6% 30 day share price return after a Blue Orca...

Zymeworks Inc. recently received U.S. FDA Fast Track designation for ZW191, its folate receptor-a–targeting antibody-drug conjugate, in advanced or metastatic platinum-resistant ovarian cancer, and formally appointed veteran biopharma finance executive Kristin Stafford as Chief Financial Officer on April 1, 2026. The combination of expedited regulatory support for ZW191 and the addition of a CFO with deep royalty and life sciences financing experience directly touches both Zymeworks’...

Sherwin-Williams earnings jolt puts guidance under the microscope Sherwin-Williams (SHW) has come under pressure after an earnings release that paired 5.6% year on year fourth quarter revenue growth and an EBITDA beat with full-year EPS guidance that fell short of analyst expectations. See our latest analysis for Sherwin-Williams. At a share price of $316.39, Sherwin-Williams has seen softer recent momentum, with a 30-day share price return of 4.1% and a 90-day share price return of 7.0%. The...

Soleno Therapeutics stock overview Soleno Therapeutics (SLNO) has drawn fresh attention after a sharp 32.3% one day move, capping a month gain of 31.7%. That kind of short term swing naturally raises valuation and risk questions for investors. See our latest analysis for Soleno Therapeutics. The sharp 32.3% one day share price return and 71.7% 7 day share price return come after a 10.8% year to date share price gain, set against a 1 year total shareholder return of about 25% decline and a...

Dividend hike and full year results put International Bancshares in focus International Bancshares (IBOC) is back on investor radars after the board approved a $0.73 per share cash dividend, a 4.3% increase, alongside the release of full year 2025 financial results. See our latest analysis for International Bancshares. At a share price of $68.26, International Bancshares has seen a 1-day share price return of 0.72% and a 1-month share price return of 2.60%, while the 1-year total shareholder...

What Brown-Forman’s recent performance could signal for investors Brown-Forman (BF.B) has drawn fresh attention after a mixed run in its share performance, with a roughly 6% gain over the past month but a negative total return over the past year. Against that backdrop, investors are weighing the company’s US$3.9b in revenue, US$807m in net income, and a value score of 4, alongside longer term total return figures that have trailed shorter term moves. See our latest analysis for...

Trex Company (TREX) has kicked off an expanded 2026 marketing push, rolling out national TV spots, lifestyle and sports integrations, and high-profile sponsorships that put its wood-alternative outdoor products and TrexPro builder network in front of a wider audience. See our latest analysis for Trex Company. At a share price of $36.04, Trex has a 7 day share price return of 1.81% but a 1 year total shareholder return decline of 32.10%, suggesting recent marketing and financing updates are...

On February 12, 2026, Crocs, Inc. reported quarterly results with earnings per share of 2.29 and revenue of US$957.64 million, both exceeding analyst forecasts. The simultaneous outperformance on both the top and bottom lines highlights how Crocs’ current business model is converting sales strength into earnings efficiency. We’ll now explore how this earnings and revenue beat may influence Crocs’ existing investment narrative around international expansion, DTC focus, and...

Ondas (ONDS) came under pressure after JCapital Research released a critical report questioning the company’s reliance on share-funded acquisitions, its path to profitability, and its governance practices, including significant CEO stock sales ahead of expected dilution. See our latest analysis for Ondas. The share price has pulled back 0.8% over the last day to US$9.52 after the short report, despite a strong 1 year total shareholder return that is more than 10x. This suggests recent...

Buyback completion and new repurchase plan frame City Holding’s latest moves City Holding (CHCO) has just wrapped up a share repurchase covering 5.64% of its stock for US$93.8 million and launched a new program authorizing up to 1,000,000 additional shares, alongside affirming its regular quarterly dividend. See our latest analysis for City Holding. Those buybacks and the affirmed dividend come after a period where the 1 year total shareholder return of 14.83% has outpaced the more modest 3...

Context for LSB Industries stock LSB Industries (LXU) has drawn fresh attention after a strong year of share price performance, with total return over the past 12 months at 185% and market value around US$1.1b. See our latest analysis for LSB Industries. At a share price of US$15.00, LSB Industries has seen strong positive momentum over the past year, with a 68.35% 3 month share price return contributing to a 184.63% 1 year total shareholder return, even after a softer 7 day share price...

Why Catalyst Pharmaceuticals (CPRX) Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has attracted attention after recent share moves, with the stock last closing at $24.98 and showing positive total returns over the past year and past 3 months. Investors are also weighing the company’s value score of 6 and its US$3b market cap, as well as its focus on commercial treatments for rare diseases through products such as Firdapse, Fycompa, and AGAMREE. See our latest analysis for Catalyst...

Incyte (INCY) is back in focus after releasing 54 week Phase 3 data for its JAK1 inhibitor povorcitinib in moderate to severe hidradenitis suppurativa, alongside ongoing regulatory reviews in the US and Europe. See our latest analysis for Incyte. Alongside the new povorcitinib data and fresh collaboration and leadership updates, Incyte’s 7 day share price return of 5.01% contrasts with a 90 day share price return decline of 11.06%, while the 1 year total shareholder return of 57.34% points to...

Tyler Technologies (TYL) is back in focus after approving a $200 million stock repurchase plan and securing a broad public safety software deployment across multiple Michigan counties, together drawing attention to both capital allocation and contract momentum. See our latest analysis for Tyler Technologies. The latest 1 day share price return of 0.25% and 30 day share price return of 9.98% sit within a tougher backdrop, with a 12 month total shareholder return of 36.98% and 5 year total...

In recent weeks, Exelixis, the Alameda-based oncology biotech, has seen several Wall Street analysts raise their earnings estimates for fiscal 2026, citing improving expectations for the business. This cluster of upward revisions, combined with Exelixis’ A-rated VGM Score and focus on difficult-to-treat cancers, has reinforced its appeal to investors who closely track analyst models and valuation metrics. Next, we’ll explore how this wave of upgraded earnings forecasts could influence...